@article{4bebf76ceb2245d8aca27bc3be8b0a54,
title = "Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer",
abstract = "We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.",
keywords = "PD-L1 expression, chemoimmunotherapy, meta-analysis, non-small-cell lung cancer, progression-free survival",
author = "Rachel Woodford and Yanni Loh and Joanna Lee and Wendy Cooper and Ian Marschner and Lewis, {Craig R.} and Michael Millward and Sally Lord and Gralla, {Richard J.} and Yang, {James C.H.} and Tony Mok and Lee, {Chee K.}",
note = "Funding Information: There is no specific funding for this research. M Millard reports being advisory board member for Bristol-Myers Squibb, Astrazeneca, Roche, Merck Sharp & Dohme. JCH Yang reports receiving honoraria and advisory fees from Eli Lilly, Boehringer Ingelheim, Roche/Genentech/Chugai, Merck Sharp & Dohme, Pfizer, Novartis, Bristol-Myers Squibb, Ono Pharmaceutical, Takeda, and As-traZeneca, and advisory fees from Bayer, Astellas, Merck Serono, Celgene, Merrimack, Yuhan Pharmaceuticals, Daiichi Sankyo, and Jiangsu Hansoh Pharmaceutical. T Mok reports receiving fees for serving on advisory boards from AstraZeneca, Roche/Genentech, Eli Lilly and Company, Merck Serono, ACEA Biosciences, Bristol-Myers Squibb, AVEO-Biodesix, Pfizer, Boehringer Ingelheim, No-vartis Pharmaceuticals, GlaxoSmithKline, Clovis Oncology, Amgen, Janssen, BioMarin Pharmaceuticals, SFJ Pharmaceuticals, Merck Sharp & Dohme, Vertex Pharmaceuticals, Oncogenex, and Celgene, consulting fees from geneDecode, lecture fees from As-traZeneca, Roche/Genentech, Eli Lilly and Company, Merck Serono, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Novartis Pharmaceuticals, GlaxoSmithKline, Clovis Oncology, Amgen, Merck Sharp & Dohme, and Prime Oncology, and holding stock in Sanomics. CK Lee reports receiving fees for serving on advisory boards from AstraZeneca, Roche, Novartis, Pfizer and Takeda; receiving travel support from AstraZeneca and CK Lee{\textquoteright}s institution receiving research grant from Astrazeneca. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2019 Future Medicine Ltd.",
year = "2019",
month = jul,
doi = "10.2217/fon-2019-0105",
language = "English (US)",
volume = "15",
pages = "2371--2383",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "20",
}
